Cargando…
Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study
Anti–tumor necrosis factor (TNF) therapy is effective in inducing remission in Crohn's disease in 60% of patients. No serological biomarkers are available, which can predict response to anti-TNF. We aimed to investigate serological markers of collagen turnover reflecting tissue inflammation as...
Autores principales: | van Haaften, Wouter T., Mortensen, Joachim H., Dige, Anders K., Grønbæk, Henning, Hvas, Christian L., Bay-Jensen, Anne-Christine, Karsdal, Morten A., Olinga, Peter, Manon-Jensen, Tina, Dijkstra, Gerard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494148/ https://www.ncbi.nlm.nih.gov/pubmed/33094957 http://dx.doi.org/10.14309/ctg.0000000000000217 |
Ejemplares similares
-
Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease
por: van Haaften, W. T., et al.
Publicado: (2017) -
Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease
por: Mortensen, Joachim Høg, et al.
Publicado: (2017) -
Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease
por: Bourgonje, Arno R., et al.
Publicado: (2022) -
Serological Biomarkers of Joint Tissue Turnover Predict Tocilizumab Response at Baseline
por: Bay-Jensen, Anne C., et al.
Publicado: (2014) -
Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)